ACSL4 and prostate carcinoma: Consistent with this observation, in two E2F1 ChIP-Seq data sets generated from isogenic RB1-proficient and -deficient prostate cancer cell models, E2F1 binding to the ACSL4 promoter was enhanced after RB depletion (Supplemental Figure 3E).